References
- De la Torre-Gomar FJ, Velasco-Amador JP, Prados-Carmona Á, et al. Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib. J Dermatolog Treat. 2024;35(1):1. doi: 10.1080/09546634.2024.2304630.
- Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443–2. doi: 10.1007/s40257-023-00764-w.
- Yan D, Fan H, Chen M, et al. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Front Pharmacol. 2022;13:950450. doi: 10.3389/fphar.2022.950450.